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Abstract
Since mite allergens are the most relevant inducers of allergic diseases worldwide, resulting in significant morbidity
and increased burden on health services, the International Collaboration in Asthma, Allergy and Immunology
(iCAALL), formed by the American Academy of Allergy, Asthma and Immunology (AAAAI), the American College of
Allergy, Asthma and Immunology (ACAAI), the European Academy of Allergy and Clinical Immunology (EAACI), and
the World Allergy Organization (WAO), has proposed to issue an International Consensus (ICON) on the clinical
consequences of mite hypersensitivity. The objectives of this document are to highlight aspects of mite biology
that are clinically relevant, to update the current knowledge on mite allergens, routes of sensitization, the genetics
of IgE responses to mites, the epidemiologic aspects of mite hypersensitivity, the clinical pictures induced by mites,
the diagnosis, specific immunotherapeutic approaches, and prevention.
Introduction
Mite allergens are able to sensitize and induce allergic
symptoms in sensitized and genetically predisposed indi-
viduals resulting in allergic rhinoconjunctivitis, asthma,
and atopic dermatitis. . The main sources of allergens in
house dust worldwide are the fecal pellets of the mite spe-
cies Dermatophagoides pteronyssinus, Dermatophagoides
farinae, Euroglyphus maynei, and the storage mites Blomia
tropicalis, Lepidoglyphus destructor and Tyrophagus putres-
centiae. Recent advances in the study of mite biology, mite
allergen properties and cross-reactivities, have provided
better approaches for the prevention and management of
diseases produced by exposure to mite allergens, including
improved diagnostic and immunotherapeutic methods [1].
In this ICON document a comprehensive review of the
major issues concerning human diseases caused by mites
will be presented, as a contribution to the understanding of
the importance of mite hypersensitivity as an important
inducer of diseases that constitute a major public health
concern all around the world.
Methodology
A working committee that included members of the par-
ticipating organizations who are actively working in the
field of mite hypersensitivity was formed, taking into
account regional representation and previous individual
publications. Members were assigned sections which,
when completed, were compiled by the project leader
and circulated to all members. After corrections were
included the final draft was submitted for approval by
the governing boards of the participating organizations.
Overview of biology
Mites and ticks are included in the subclass Acari, which
forms one of the most abundant and diverse biological
groups within the arachnids (Arthropods) (Fig. 1). Its
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name derives from the Latin word acarus, which in turn
derives from the Greek name Akari, whose first known
mention is attributed to Aristotle (, Historia Animalium,
Book 5, Chapter 32). He most likely used this name to
mention the mite species Carpoglyphis lactis. Mites are
characterized by having four pairs of legs, such as
spiders and scorpions (insects have three pairs of legs;
crustaceans five pairs of legs) which are relatively smaller
than their bodies. Most of the mite species have a size of
less than 1 mm (most house dust mite species are below
half a millimeter). Mites can be considered as one of the
oldest terrestrial animals. One of the first known mite
fossils (identified as Protoacarus crani, Raford) originates
from the Devonian period, nearly 400 Ma ago. Approxi-
mately 30,000 species of mites, placed in more than
1,700 genera, have been described. However, it is consid-
ered that the number of undescribed species could be
more than 100,000. Mites are distributed worldwide and
have competed with insects for aquatic and terrestrial
habitats. They can be found in the soil of forests and
grasslands, or on any organic waste. Many species spend
part of their life cycle in trees and shrubs, while others
live in caves or have adapted to live in hot springs.
Depending on the species, they feed on plants, fungi,
algae, organic matter, animal waste, other arthropod,
nematode, or infest the exterior and interior of all kinds
of animals (insects, reptiles, birds and mammals) [2].
Most domestic mites belong to the order Astigmata.
They do not have external respiratory openings or stig-
mata (Astigmata means “no stigma”). Their small size
makes the ratio between the body surface and its interior
sufficient to allow efficient gas exchange through the
skin. In other orders, breathing could also take place
through body openings (1–4 stigmas), which are located
in the front half of the body, or through a trachea [3].
Mites have developed a digestive tract, including a
mouth and mouth parts, salivary glands, and an intes-
tine, consisting of esophagus, small intestine, along with
Fig. 1 Taxonomy of Mites with Allergenic Relevance
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a large intestine and an anal opening. Their digestive
system produces spherical fecal particles (diameter of
about 20 μm) wrapped in a peritrophic membrane,
which are the main vector of mite allergens. Mites most
commonly found inside the houses worldwide include
D. pteronyssinus, D. farinae, E. maynei and B. tropicalis
[4, 5]. They feed mainly on human scales and other
micronutrients. The amount of human flakes released
daily by an adult is of 0.5 to 1 g, and therefore, it is a
very abundant food source. In addition to human skin
scales the diet may also include: fungi and other constit-
uents of the skin microbiota, body fragments of insects
(beetles, cockroaches, moths), etc.
The life cycle of dust mites and some of the storage
mites consists of five stages (egg, larva, protonymph, trito-
nymph and adults). In each stage, there is an active period
followed by another, shorter, quiescent stage, before a new
stadium emerges from the old exoskeleton. The quiescent
period protonymph in dust mites can be long lasting as it
is resistant to drying and allows mites to survive long dry
periods (several months). This stage remains attached to
the substrate and cannot be removed by vacuuming. Some
storage mites (L. destructor, A. siro) have an additional
stage (deutonymph or hipopus) which allows them to
resist unfavorable weather or nutritional conditions.
The life cycle of the mites is directly dependent on the
temperature. Microhabitats where mites are found in
homes are not uniform in temperature and relative hu-
midity and the temperature fluctuates within a micro-
habitat. Thus, their development at low-temperature
(on the floor) is lower as compared to their develop-
ment in warmer conditions (mattresses, or sofas). For
D. pteronyssinus, a cycle from egg to adult takes about
122 days at 16 °C (75% RH) while it only takes 15 days
at 35 °C [6, 7].
An allergenic role has been attributed to house dust
since the early years of the past century. This allergen-
icity was responsible for a large number of respiratory
allergic diseases worldwide. The importance of these
allergic manifestations induced by the inhalation of
house dust present in soil, mattresses, carpets, rugs,
sofas, and comforters was thoroughly studied by differ-
ent researchers in an attempt to identify the main com-
ponents responsible for this allergenic effect. In 1921,
Kern refers for the first time to the importance of house
dust in allergic manifestations [8]. In 1922, Cooke specu-
lates about the existence of allergens of unknown origin
and nature in house dust allergen and extracts were pre-
pared for desensitization studies [9]. In 1924, Storm Van
Leeuwen associated the dust allergy phenomenon with
certain climatic circumstances, as spectacular clinical
improvements were observed when patients were moved
to high mountain climates with low relative humidities
[10]. The occasional discovery of mites in house dust
was pointed out by different investigators on several
occasions. The presence in house dust of mites of the
genus Dermatophagoides farinae was indicated for the
first time in 1964 by Oshima [11]. However, Voorhorst
and Spieksma in 1964, showed that house dust contains
mite species with a high allergenic power, which could be
responsible for the allergenicity of house dust [12]. Fain
identified in 1966 the mite D. pteronyssinus as the
main allergen source responsible for numerous re-
spiratory allergies induced by the inhalation of house
dust [13].
Mites found worldwide in human premises can gener-
ally be grouped into house dust mites and storage mites.
They are found in carpets, fabrics, upholstery, pillows
and mattresses. Blomia tropicalis, was formerly known
as a storage dust mite, but is now also accepted as a
house dust mite as it is found extensively in dust from
homes in tropical and subtropical countries. Storage
mites include Glycyphagus domesticus, Lepidoglyphus
destructor, Blomia kulagini, Tyrophagus putrescentiae,
Acarus siro, Suidasia pontifica, Glycycometus malaysien-
sis, Aleuroglyphus ovatus and Thyreophagus entomopha-
gus. Storage mites are commonly found worldwide in
storage facilities for grains such as wheat, corn, oats,
barley and hay. They may contaminate or invade and
thrive in processed foods made from the grains (e.g.,
flour, cereals and baking mixes) when these products
become moist or are stored in humid environments. In
recent years, the new term domestic mites has been
coined to include all mite species present in the indoor
environment that can sensitize humans. It includes all
the above mentioned species which can be regularly
found in the indoor environment, including bedding,
sofas, kitchen floors, etc.
Mite identification studies worldwide have confirmed
that most mite species are present in most sites where
these studies have been conducted, including the Northern
and Southern hemispheres. Mites are almost absent in the
artic regions, or in highly cold and dry climates, such as in
high altitude areas in the Alps. There is ample evidence
that many mite species can sensitize exposed individuals
and produce allergic diseases. It has been suggested that
any mite species which is in contact with a genetically
prone individual, can induce sensitization. Mite allergens
can be detected in many areas of the home, including
beds, carpets, upholstered furniture and clothing. Leather-
covered couches, wood furniture, and bare floors contain
fewer mites. Beds are the perfect habitat for mites, since
they provide the ideal temperature, food and moisture for
their proliferation, and allergens they produce accumulate
deep inside mattresses and pillows, especially when they
are old. Information on the distribution of house dust
mites provides valuable data to design environmental
control strategies.
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Allergy to mites is a global health problem recognized
by the World Health Organization, which affects mil-
lions of people around the world. The discovery of the
cause-effect relationship between sensitization to mites
and asthma is relatively recent, approximately 50 years.
In these years there have been significant advances in
the identification and characterization of mite allergens
and many have been purified and sequenced. Similarly,
there has been great progress in the standardization of
allergenic extracts of several mite species for diagnosis
and treatment, and the clinical efficacy of immunother-
apy using extracts of several species of mites has been
demonstrated.
Mite allergens
The World Health Organization and the International
Union of Immunological Societies (WHO/IUIS) allergen
nomenclature sub-committee currently includes up to
31 D. pteronyssinus and D. farinae allergens in the sys-
tematic nomenclature, as well as 13 allergens from
Blomia tropicalis and multiple allergens from storage
mite species [14]. Most of these allergens have been
defined by IgE binding or skin test reactivity and have
been cloned, sequenced and expressed as recombinant
proteins for further analyses [15]. The three dimen-
sional structures of several important allergens have
been determined by X-ray crystallography or nuclear
magnetic resonance spectroscopy and the atomic co-
ordinates have been deposited in the protein database
(PDB) (Fig. 2) [16].
The finding that the individual allergen components
make characteristic contributions to the overall anti-mite
IgE response of most allergic subjects [15] suggests that
the biological functions of the individual mite allergens
and how they are delivered contribute to their allergen-
icity. The group 1 allergens of Dermatophagoides spp.
(Der p 1 and Der f 1) are cysteine proteases that have,
when enzymatically active, the ability to be adjuvants for
Th2 inflammatory responses via numerous proposed
mechanisms [15, 17]. The apparent low allergenicity of
cysteine protease allergens of other mite species, and the
susceptibility of cysteine proteases to oxidative deactiva-
tion however needs to be considered. The group 2 aller-
gens have structural and functional homology to MD-2,
the LPS binding component of Toll Like Receptor 4
(TLR-4). In a mouse model of transient sensitization, Der
p 2 plus endotoxin could drive airway Th2 inflammation
via TLR-4 and thus could similarly promote IgE antibody
responses [18]. In contrast, sensitization via the skin was
TLR4 independent in another mouse model [19].
From their structures, other mite allergens (Der p 5,
Der p 7, Der p 21) appear to be lipid-binding proteins.
These allergens could use attached lipid moieties to
interact with the innate immune system or otherwise act
as adjuvants for IgE responses [20, 21]. Recently, another
major allergen, Der p 23, was identified as a peritrophin
homologue associated with the chitinous peritrophic
membrane on the surface of mite faeces thus providing
an association with the known Th2 adjuvant chitin [22].
The Dermatophagoides spp. group 1, group 2 and
group 23 allergens, are immunodominant based on the
prevalence and magnitude of IgE responses determined
by gravimetric estimations or comparative titrations with
proteins of known allergenicity [22–26]. Using these cri-
teria, the group 4, 5, 7 and 21 allergens exhibit medium
or mid-tier allergenicity [22, 24–27] and the other
groups minor or unknown allergenicity [15, 24, 25]. The
group 1 and 2 allergens typically bind 50–70% of the
amount of IgE that binds to HDM extracts [23, 24, 26,
27] and while Der p 23 has consistently shown similar
IgE binding prevalence to the group 1 and 2 [22, 25–27],
not all studies have found high titres [26, 27]. The
medium or mid-tier allergens bind IgE in 30–50% of
mite-allergic patients and appear to account for most of
the residual IgE binding of extracts [15, 24]. The Derma-
tophagoides spp. allergens are listed in Table 1 in the
context of their known allergenicity.
Children with stable asthma and those with a propen-
sity to be hospitalised for recurrent and persistent
asthma have been found to have a similar profile but
with a higher although overlapping amount of IgE bind-
ing [24]. However, atopic non-asthmatic subjects have
been found to bind IgE to fewer allergens than asth-
matics, perhaps due to their overall lower IgE titres [25].
The three immunodominant allergens (Der p 1, Der p 2,
Der p 23) also show the highest levels of reactivity in
other assessments of allergenicity including skin testing,
basophil histamine release assays and RAST inhibition
assays [22–28].
The availability of purified allergens, together with sensi-
tive, high-throughput immunoassays (ELISA,MARIA and
Microchips) for making allergen measurements, has
important clinical applications (Table 2). These assays
have direct applications for improving allergy diagnos-
tics and the formulation and testing of therapeutics.
Moreover, sophisticated analytical methods, such as
mass spectrometry, now enable precise determinations
of allergen purity and isoform distribution within mite
extracts and within purified allergens themselves. Crys-
tallographic studies have determined the contact resi-
dues for monoclonal antibody epitopes on the Group 1
allergens, as well as the surface location of Der p 1 and
Der f 1 isoforms [28]. This work is currently being ex-
tended to identify IgE antibody binding sites. Progress
in structural biology will allow the development of new
forms of immunotherapy using strategies based on un-
modified recombinant allergens, hypoallergens or T
cell peptides.
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Routes of sensitization and pathogenesis
Sensitization to house dust mites (HDM) in early life is
associated with subsequent persistent allergic asthma in
childhood and reduced lung function [29, 30]. Although
the link between sensitization and allergic disorders is
still poorly understood, however, an understanding
the nature and mechanism of allergen sensitization
provides insights into primary preventive strategies
for dust mite allergy.
Sensitization through the respiratory airway
Being an inhalant allergen, conventional wisdom indicates
that the airway mucosa is the main route of HDM allergen
sensitization. There is evidence of a dose–response
Fig. 2 X-ray crystal structure of Der p 1 in complex with Fab fragments of three anti-Der p 1 monoclonal antibodies, 5H8, 10B9, and 4C1. Reproduced
from: Tomasz Osinski, Anna Pomés, Karolina A. Majorek, Jill Glesner, Lesa R. Offermann, Lisa D. Vailes, Martin D. Chapman, Wladek Minor, Maksymilian
Chruszcz. Structural analysis of Der p 1-antibody complexes and comparison with complexes of proteins or peptides with monoclonal antibodies. J
Immunol 2015; 195: 307–316. DOI: 10.4049/jimmunol.1402199. Figure 1 reused with permission. Copyright 2015. The American Association of
Immunologists, Inc
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relationship between exposure and sensitization to HDM
allergens. However, this dose response relationship is a
non-linear bell-shaped curve, with higher concentrations
being protective [31]. It has been postulated that the pro-
tective effect of high levels of dust mite exposure is related
to the concomitant increased levels of immune modifiers,
such as endotoxins and fungal beta-glucans [32]. One
study showed that the highest rates of sensitization oc-
curred between levels of 3.5 and 23.4 μg/g dust [33].
Hence, it has been suggested that a ‘safe’ level for dust
mite avoidance in primary prevention of sensitization
studies is a maximum of 2 μg of allergen per g of dust.
HDM sensitization is likely to occur when allergens
are airborne, however, measurement of airborne aller-
gens, has been challenging. Although not ideal, the
measurement of dust mite allergens in house dust is
used as the index of exposure to these allergens. Unlike
cat allergen or pollen allergens, dust mite particles are
predominantly large particles (>20 μM), and therefore
settle rapidly. For example, airborne Group 1 and Group
2 allergens were measurable for only 20 min after agitation
or disturbance (eg. cleaning) of dust mite reservoirs [34].
The mechanism by which large dust mite allergen par-
ticles reach the respiratory tract to induce sensitization
and allergic reactions has been an issue of debate. None-
theless, it has been demonstrated that minute quantities
of dust mite allergen particles that are within the respir-
able range (1.1 to 4.7 μM) are airborne after disturbance
of dust mite reservoirs (eg. by vacuum cleaning without
a filter) [35]. The quantity of airborne allergen was how-
ever very small and an amplified ELISA system was
required to detect these concentrations. This is, however,
the likely mechanism by which dust mite allergens reach
the lower respiratory tract.
Dust mite allergens are contained in mite fecal pellets
and mite body parts. These allergens together with non-
allergenic components are powerful inducers of TH2
responses resulting in the induction of IgE antibodies.
The list of allergens with inherent adjuvant effects giving
rise to IgE sensitization are summarized in Table 3. The
immunostimulating effects of these particles arise from
the allergens themselves. The major Group 1 allergens
(eg. Der p 1 and Der f 1) are cysteine proteases that
increase the permeability of the respiratory epithelium
by enzymatic digestion of the tight junctions [36]. A
similar phenomenon was observed in the skin, where
the Der p 1-like cystein protease papain percutaneously
led to instant innate inflammation, while notably, spe-
cific sensitization was independent on the enzymatic
function [37]. More recently Group 2 allergens (eg. Der
p 2 and Der f 2) have been shown to be a homolog of
the adapter protein MD-2 (a co-receptor of the toll-like
Table 1 Allergens from Dermatophagoides species
Immunodominant Mid-tier Minor Unknown
1 Cysteine protease 4 Alpha amylase 3 Trypsin 14 Large lipid transfer protein
2 ML domain protein 5 Unknown coiled coil bundle 6 Chymotrypsin 22 ML domain protein
23 Peritrophin homologue 7 LPS binding protein homologue 8 Glutathione-S-transferase 24 Cytochrome c reductase binding protein
21 Group 5 homologue 9 Collagen serine protease 25 Triosephosphatase isomerase
10 Tropomyosin 26 Myosin alkali light chain
11 Paramyosin 27 Serpin
13 Fatty acid binding 28 Heat shock protein
16 Gelsolin 29 Cyclophilin
17 Unknown EF hand protein 30 Ferritin
31 Cofilin
32 Pyrophosphatase
33 Alpha tubulin
aGroup 12 and 19 allergens have not been found for Dermatophagoids spp
bNo quantitative assessments of IgE binding have been reported for the Unknown groups due to the tests used or the nature of the allergen preparations
Table 2 Clinical applications of purified mite allergens and
assays
•Improved allergen standardization and formulation. To develop HDM
extracts with consistent amounts of major allergens for diagnosis and
therapy.
•To develop formulations of purified allergens for molecular diagnostics
with useful discrimination and quantitation of IgE antibody levels and
to enable the measurement of allergen-specific IgG antibodies as potential
prognostic markers for diagnosis.
•To provide environmental exposure assessments to improve patient
education about mite allergen exposure and asthma. To develop
objective assessments of allergen control procedures, methods and
devices. To understand the aerodynamics and distribution of mite
allergens.
•To facilitate clinical research on the cellular basis of the immune response
to dust mites, including T-cell responses, antigen presentation and local
immune responses in the respiratory epithelium. To expand knowledge
of mite allergen interactions with the innate immune system.
•To improve the formulation, reproducibility and potency of mite
allergen immunotherapeutics and to develop new strategies for
immunotherapy and true prophylactic vaccines.
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receptor) (TLR) that can facilitate lipopolysaccharide-
mediated signaling throughTLR-4 [18]. Furthermore, these
dust mite particles also contain pathogen-associated mo-
lecular patterns (PAMPS) such as mite DNA, bacterial
DNA and endotoxin, which act to activate the innate im-
mune system and are therefore adjuvants of the allergic
response.
These effects of dust mite allergens on epithelial cells
result in the release of epithelial-derived Th-2 promoting
cytokines including thymic stromal lymphopoetin
(TSLP), IL-25 and IL-33 [38]. A simplified model of
HDM-induced innate immune activation leading to dust
mite allergen sensitization is depicted in Fig. 3.
Sensitization through the skin
More recently, the skin has also been recognized as a
route of allergen sensitization, particularly when the skin
barrier is disrupted by eczema. In support of this, it has
been shown that there is a positive correlation between
the rate of aeroallergen sensitization and transepidermal
water loss (TEWL) in infants with eczema [39]. In fact,
filaggrin mutations, which confer susceptibility to ec-
zema, have also been shown to be a risk factor for aller-
gen sensitization [40]. In animal models, overproduction
of the cytokine TSLP by eczematous skin promotes air-
way sensitization to house dust mites, thereby triggering
allergic asthma [41]. Taken together, these observations
would explain the progression from eczema to asthma,
which is known as the atopic march.
The immune mechanisms by which HDM allergens in-
duce a Th2 activity through the cutaneous epithelium
are likely similar to those occurring at the respiratory
airway. HDM allergens are likely to penetrate the skin
barrier via direct proteolytic activity of HDM allergens
(eg. Der p 1) and its capacity to bind to lipids (eg. Der p
2). Additional adjuvant properties of allergens and mole-
cules within dust mite particles engage the innate
system, particularly through dendritic cells, which results
in Th2 skewing and IgE production [42] (Fig. 3).
Summary
The molecular properties of house dust mite allergens
together with exogenous agents contained in dust mite
fecal particles render HDM as the source of highly po-
tent allergens. Sensitization occurs mainly through the
respiratory tract. However, recent evidence indicates that
the eczematous skin is also an important route and may
be a mechanism to explain the atopic march.
Genetics of IgE responses to mite allergens
The specific IgE response is a complex trait highly influ-
enced by the environment. Because of its close relation-
ship with allergic diseases, the genes influencing this
phenotype are of great basic and clinical interest. The
IgE molecule probably evolved from amphibians IgY
[43] and a functional IgE targeting environmental com-
ponents (allergens) started when an appropriate set of
genes controlling specific IgE production was available.
Since then, the number of genes influencing IgE has
evolved to the current repertoire, which includes some
related to general mechanisms of innate and adaptive
immune responses and others determining specificity.
IgE hyperresponsiveness to mite allergens is one of the
most important asthma-associated phenotypes and is a
risk factor for asthma and other allergic diseases. The
first attempts to identify genes controlling IgE responses
were focused on the Human Major Histocompatibility
Complex (MHC/HLA) because of its relevant relation-
ship with the adaptive immune response. The associa-
tions of DRB1, DQB1 and DPB1 alleles with almost all
kind of allergen extracts and purified molecules have
been huge. In 1990, an affected sib pair analysis study
showed that IgE hyperresponsiveness to D. farinae in pa-
tients with allergic asthma was linked to MHC [44].
Table 3 Key dust mite allergen groups with known biochemical identity conferring allergenicity
Allergens Groups Biochemical Identity Mechanism of TH2immune induction
Group 1 Cystein protease Increased permeability through disruption of airway and cutaneous epithelial tight junctions
Group 2
Der p 2, Der f 2
MD-2 like lipid-binding protein Molecular mimicry of MD2 and DC activation via TLR4
TLR2 activation on DC
Group 3
Der p 3, Der f 3
Trypsin-like serine protease Increased permeability through disruption of airway and cutaneous epithelial tight junctions
PAR-2 activation in airway epithelial cells and keratinocytes
Group 5
Blo t 5, Der p 5, Der f
5
Lipid binding protein TLR activation?
Group 6
Der p 6, Der f 6
Chymotrypsin-like serine
protease
Increased permeability through disruption of airway and cutaneous epithelial tight junctions
PAR-2 activation in keratinocytes
Group 7
Der p 7, Der f 7
Lipid binding Protein Molecular mimicry of lipid binding protein and dendritic cell activation via TLR2, 3, 4
Group 9
Der p 9, Der f 9
Collagenolytic protease Increased permeability through disruption of airway and cutaneous epithelial tight junctions
PAR-2 activation in airway epithelial calls and keratinocytes.
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Several years later, a genome wide search found strong
evidence of linkage between the specific IgE responsive-
ness to D. pteronyssinus and chromosomes 6p21 (HLA-D
region), 2q21-q23, 8p23-p21, 13q32-q34 and 5q23-q33 in
Caucasians families [45]. The role of HLA on the IgE
response to this mite was further analyzed by the same
authors, evaluating the IgE responses to several allergen
components of D. pteronyssinus extract [46]. Linkage
studies involving HLA loci and mite IgE responses have
been replicated in other populations [47, 48].
In a case–control study the frequency of allele HLA-
DPB1*0401 was remarkably decreased in patients with
IgE hyperresponsiveness to mite allergens, suggesting
that it could be suppressing this phenotype in the non-
allergic population [49]. In addition, the protective role
of other DPB1 allele (*0201) in controlling IgE response
to mite has been reported [50]. Other associations in-
clude IgE hyperresponsiveness to B. tropicalis and D.
pteronyssinus purified allergens with HLA-DRB1*03 in
non-related subjects [51] and family studies [52], although
Fig. 3 Simplified model of the HDM-induced innate immune activation leading to IgE sensitization in the airways. The induction ofTh2 immunity
by HDM allergens results from the stimulation of different innate immune pathways. HDM protease allergens specifically cleave protease sensitive
receptors including protease-activated receptor (PAR)-2, disrupt epithelial barrier to gain access to dendritic cells (DCs), and cause tissue injuries
to release danger-associated molecular patterns (DAMPs) such as adenosine triphosphate (ATP) and uric acid. Contaminating microbial pathogen-
associated molecular patterns (PAMPs) associated or not with lipid-binding allergens trigger numerous pathogen recognition receptors (PRRs)
which can produce also DAMPs whereas HDM glycan activation of DCs is mediated through C-type lectin receptors (CLR) ligation. These signaling
pathways result in the upregulation of innate cytokines/chemokines such as IL-1β, IL-6, thymocyte stromal lymphpoetin (TSLP), IL-25, IL-33, GM-CSF, or
CCL20 to recruit and activate inflammatory cells and to induce Th2 differentiation. TSLP mediates OX40L and IL-4 expression in DCs and
basophils, respectively, to initiate a Th2-polarized response. IL-25 and IL-33 are strong activators of innate lymphocyte cells (ILC2s) which
secrete theTh2 cytokine IL-13 to induce IgE secretion by B cells [40]. Modified from: Alain Jacquet, Innate immune responses in house dust mite allergy.
IRSN Allergy 2013; 2013: 735031. DOI: 10.1155/2013/735031. The authors used Fig. 2 under the Creative Commons Attribution License
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the role of other HLA alleles has also been documented
[53–56]. It is worth to mention that the 6p21 region
contains additional genes (e.g. butyrophilin-like 2, BTNL2)
that have been associated with the risk of mite sensitization
[57] but it is unclear whether those associations were due
to the linkage disequilibrium with HLA alleles or other yet
unclear mechanisms. In populations perennially exposed
to mite allergens it is common to find subjects monosensi-
tized to particular mite allergens while others might
recognize several allergenic components. The detailed
mechanisms explaining how the MHC alleles influence
those phenotypes remain to be elucidated. The availability
of purified allergen molecules with known clinically rele-
vant epitopes, as well as sequencing approaches for defin-
ing HLA alleles, will help to better define the role of this
genetic region on the specificity of IgE responses.
As soon as the complex nature of IgE synthesis became
more evident, the discovering of “out-MHC” genes influ-
encing IgE was more frequent. Polymorphisms in Th2-
genes, for instance those in the gene encoding interleukin
4 at the 5q31 locus [58, 59] and the signal transducer and
activator of transcription 6 (STAT6) [60, 61] have been
replicated in different populations. Associations with mite
sensitization have been also reported with polymorphisms
in the genes encoding interleukin-18 (IL18) [62, 63], leu-
kotriene C4 synthase (LTC4S) [64], nitric oxide synthase 1
(NOS1) [65], interleukin 4 receptor alpha (ILR4A) [58],
dendritic cell associated nuclear protein 1 (DCNP1) [66],
interferon regulatory factor 1 (IRF-1) [67], CD14 [68, 69],
Janus kinase 2 (JAK2), GATA binding protein 3 (GATA3),
CD40 and interleukin 5 receptor alpha (IL5RA) [70], all of
them participating in any of the multiple steps of IgE syn-
thesis. The significant associations with polymorphisms in
innate immune genes suggest that genetic effects exert
their influences at very early phases of the response. These
loci include the complement component 3 (C3) associated
with the specific IgE levels to D. pteronyssinus [71]; the
myeloid differentiation factor 2 (MD-2) associated with
the specific IgE levels to Der p 2 [72]; and the nucleotide-
binding oligomerization domain containing 1 (NOD1)
associated with mite sensitization [70].
For a long time the search for IgE modulating genes
has been based mainly on candidate gene approaches,
but in the last decade, genome wide association studies
(GWAS) and gene expression analyses revealed associa-
tions with mite sensitization in new chromosomal regions
[73–76] and confirmed the role of previously described
HLA alleles [61, 77]. The associations detected by GWAS
include the protein kinase domain containing, cytoplasmic
(PKDCC) with allergen sensitization in Europeans [73];
thymic stromal lymphopoietin (TSLP) and leucine rich
repeat containing 32 (LRRC32) with sensitization to D.
pteronyssinus and B. tropicalis in Singapore (ethnic
Chinese) [75]. There are still regions to be fine-mapped
because the underlying genes in the associated loci are
unknown. That is the case of rs10142119 associated
with the sensitization to D. farinae in Koreans [76] and
rs10174949 associated with mite sensitization in Lithu-
anians (2p25.1) [78].
Some GWAS pooled individuals with mite-sensitization
and those with other specificities in order to increase
power; however this makes very difficult to dissect which
genes are specifically related with the susceptibility to mite
sensitization [61, 74]. GWAS, together with comparative
mRNA expression analyses between mite-sensitized
asthmatics versus mite-sensitized subjects without asthma,
are also revealing divergent gene sets and pathways for
these phenotypes [79] in agreement with the fact that
sensitization to allergens (atopy) does not necessarily in-
duces allergic symptoms. Nowadays the search for genes
controlling the specificity and intensity of specific IgE re-
sponses continues, with whole-genome sequencing ap-
proaches and the investigation on epigenetic influences on
the forefront.
Since allergen exposure varies according to the geo-
graphic region, it can be anticipated that genetic epidemi-
ology studies on the same genes but in distinct locations
can obtain different results. For example, IL-4 is an
important candidate gene for asthma and atopy sus-
ceptibility. In Caucasians the effect of IL-4 C-590 T
on mite sensitization was dependent of Der p 1 levels.
The rare allele T confers a high risk of sensitization
only in children exposed to high levels of Der p 1
while the reference allele C was not associated with
mite sensitization, independent of the level of allergen
exposure [80]. Similar findings have been obtained
with the polymorphisms in the gene encoding inter-
leukin 10 (IL-10), which were significantly associated
with specific IgE levels to Der p 1 only if effect modi-
fication by allergen exposure levels was considered in
the model [81].
In addition to the detection of specific IgE to mites as
an outcome, the genetic influences on the immune
response to mites have been supported by cell assays
showing that upon stimulation with mite allergens, the
peripheral blood mononuclear cells produce different
cytokine levels depending on the carrier status of risk
genotypes [82, 83]. Besides, recent studies revealed that
epigenetic changes might influence the susceptibility to
mite sensitization by modifying DNA methylation in B
cells [84], and the hypomethylation of the interleukin 13
gene [85]. Allergen specific immunotherapy has been also
found able to change DNA methylation levels at the fork-
head box P3 gene (FOXP3) and, by improving the func-
tion of T regulatory cells, modify the IgE response to
mites [86]. Hence, environmental exposures affecting the
epigenome or polymorphisms affecting the interaction
between the genome and the epigenetic machinery may
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play a role in modulating the gene-environment signals
that lead to mite sensitization.
Defining the genetic variants underlying complex traits
has its intrinsic scientific relevance; in addition, when
associated with diseases, polymorphisms are expected to
be useful for evaluating the relative importance of the
genetic component in multifactorial diseases such as
asthma. However, although mite sensitization is one of
the most confirmed risk factors for asthma, the impact
of the involved polymorphisms in relation to other herit-
able traits also influencing the pathogenesis of the
disease remains to be established, which makes difficult
detecting the real effect and heritability of the whole
genetic component. Therefore, the usefulness of the
variants described in this section as early predictors of
mite-induced asthma may be very limited. However, the
knowledge of so many variants potentially influencing
the IgE response to mite allergens could help to answer
fundamental questions of immunology such as the origin
of allergenicity.
Epidemiology
House dust mite sensitization has frequently been shown
to be strongly associated with the presentation of allergic
airway diseases [87], but its significance varies geograph-
ically [88], by ethnicity [89], age-group [90] and environ-
ment [91]. Calderon et al. [92] noted that the prevalence
of house dust mite sensitization reported in the litera-
ture needs to be distinguished between those estimated
from unselected (random individuals within) populations
and studies focused within groups of selected symptomatic
individuals with diagnosed allergic conditions. Additionally,
differences in diagnostic tools, end-points, and terminolo-
gies used confound the estimates further.
The European Community Respiratory Health Survey
I evaluated more than 15,000 adults aged 20–44 years,
living in 35 centers in 15 developed countries. This study
reported that the prevalence of house dust mite (Derma-
tophagoides pteronyssinus) sensitization assessed via skin
prick testing ranged from 4.8% (in Albacete, Spain) to
36.8% (in Hawkes Bay, New Zealand), with a median
between centers at 21.7% [93]. In contrast, The First
International Workshop on Dust Mite Allergens and
Asthma held in 1987 had already reported sensitization
figures amongst asthmatics between 45 and 85% while
in controls those were 5 to 30% across multiple studies
[94]. Amongst the developing as well as tropical re-
gions, Caraballo et al. [95] summarized the sensitization
range to be between 10.8% (in a cross sectional popula-
tion in Butajira, southern Ethiopia) [96] to more than
70% (in Singapore) [97]. While sensitization is highly
prevalent in selected populations, only a proportion of
them will present with clinical symptoms. Amongst
asthmatic cohorts in the tropics, however, it is common
to see mite sensitization prevalences of above 80 or
even 90% [98, 99].
A key feature of mite sensitization in the tropics is the
larger repertoire of specific mite allergens that the atopic
individuals are sensitized to [100], possibly due to the
presence of a more diverse repertoire of mites being
co-dominantly present in the environment (e.g., the
concurrent presence of both Blomia tropicalis and
Dermatophagoides spp.) [100] as well as host genetic
factors (with family history being the strongest pre-
dictor of allergic diseases) [101]. This is in contrast to
the predominant Group 1 and/or 2 house dust mite
specific responses in the temperate regions (with more
than 70 and 80% of house dust mite allergic patients hav-
ing specific IgE to these allergens, respectively) [26].
Nevertheless, Batard et al. reported that between 20 and
47% of 1302 house dust mite allergic American, Canadian,
European, and Japanese patients evaluated also have IgEs
to allergens from groups 4, 5, 7, 13, 15, 21, and 23, and
this would have implications for the design, production
and standardization of dust mite allergen immunotherapy
extracts [26].
To illustrate the natural history of dust mite sensitization,
several cohort and cross sectional studies in Singapore
are summarized. In a birth cohort in Singapore, the
clinical phenotype (eczema and wheeze) with concomi-
tant allergen sensitization in the first 2 years of life
were strong predictors of atopic disorders at 5 years
[102]. At 3 years of age, 31.4% of atopic individuals in a
cross sectional study were already sensitized to house
dust mites [103]. House dust mite sensitization in toddlers
(age 2–5 years) predict persistent wheeze in children be-
tween 8–14 years old [104]. By 14 years of age, the major-
ity of atopic individuals (more than 90%) were sensitized
to house dust mites, many of them to multiple species of
dust mites [97]. Interestingly, Kidon et al. observed that
children with allergic rhinitis and concomitant atopic
dermatitis show a preferential sensitization to the Derma-
tophagoides mites, while Blomia tropicalis sensitization is
more prominent in children with pure respiratory allergy
[105]. In addition, IgE response to a larger repertoire of
specific house dust mite allergens is associated with the
presence of multi-organ allergic comorbidities (asthma,
with allergic rhinitis and/or atopic dermatitis) among
children in the tropical environment [100]. It was also
observed that migrants originating from non-tropical
countries had initially low sensitization rates for
house dust mites when they first arrived in Singapore,
but these rates increased as they spend more time
and reside in the country [87]. This increase was con-
comitantly accompanied by an increase in airway al-
lergic diseases [87].
Colloff estimated conservatively that 1–2% of the
world’s population (65–130 million people) suffer from
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allergies to house dust mites [106]. This may probably
be under-estimated by several folds. Mimicking the signifi-
cant increase over the last few decades of inhalant allergen
induced airway allergic diseases in the “” “Western” world,
dust mite associated allergic conditions are also observed
to be rising in the developing regions [107] with increased
urbanization and adoption of more “westernized” lifestyle.
In many of these regions, house dust mites are already the
most common cause of sensitization, the specific IgE
levels are generally the highest titres, and sensitization to
dust mite allergens is usually the strongest predictor of
allergic airway disease [87, 103]. With Asia and the devel-
oping world making up more than two thirds of the
world’s population, dust mite allergy would likely be an
even more significant cause of morbidity afflicting billions
of people worldwide in the future.
Clinical pictures: Asthma, Rhinitis/Rhinosinusitis,
Atopic dermatitis, Anaphylaxis
Asthma
Asthma is a major global health problem contributing
greatly to socio-economic burden. WHO estimates that
it is the most common non-communicable disease
among children and, at least, 235 million people cur-
rently suffer from asthma worldwide [108].
According to latest GINA definition, “Asthma is a
heterogeneous disease, usually characterized by chronic
airway inflammation. It is defined by the history of re-
spiratory symptoms such as wheeze, shortness of breath,
chest tightness and cough that vary over time and in in-
tensity, together with variable expiratory airflow limita-
tion” [109].
The main causes of asthma are not completely eluci-
dated, but the genetic predisposition of the patient with
an appropriate environmental exposure to inhaled sub-
stances and pollutants are important risk factors for
asthma. Many environmental exposures have been linked
to asthma causation, including allergens, tobacco smoke,
chemical irritants, pollution, dietary and physical factors
as well as respiratory infections [110, 111].
Recently Dick et al. [110] published a systematic review
that reports contradictory data regarding HDM exposure
and risk for asthma. For instance, Celedon et al. [112] re-
ported that increased HDM (≥10 μg/g) early life exposures
was associated with increased risk for asthma at 7 years
old (OR 3.0). Three other studies did not find an associ-
ation between exposure in infancy and asthma at 3, 6–7
or 8 years of age [110].
The effects of HDM on asthma exacerbations and
whether interventions aimed at exposure reduction can
significantly improve symptoms are also controversial
[113].
One of the most important goals now is to identify major
settings of exposure and provide feasible interventions to
reduce allergen to levels that improve health outcomes.
Dust mites tend to live in humid and warm climates and
are around all year long but higher in summer due to hu-
midity [114]. Therefore, interventions should be compre-
hensive and present through different seasons. One recent
study looked at different levels of exposure to dust mite in
different locations to identify the major sources and set-
tings of exposure that need to be tackled. The highest aver-
age exposure (1117 pg/m3, 95% CI: 289–4314) occurred
on public transport and the lowest overnight in bed
(45 pg/m3, 95% CI: 17–117), which contributed only 9.8%
(95% I: 4.415.1%) of total daily exposure. They concluded
that the highest levels of exposure to dust mites during
24 h were present in public transportation and the lowest
levels occurred during the night in bed. Their results sug-
gest that proximity to people causes more exposure than
beds, which is controversial to the previous studies identi-
fying beds as major sources of exposure [115]. This is im-
portant from an interventional standpoint because clearly
sites with higher exposure need more attention than those
with less levels of allergens.
Many studies have looked at the effects of home-based
interventions for allergen exposure reduction on asthma
improvement and a landmark study identified that a
multi-faceted approach in inner-city children was effect-
ive in reducing morbidity, cost-effective, and had lasting
benefits [116]. Interventions such as caretaker education,
use of allergen impermeable covers for mattresses and
vacuum with a high efficiency particulate air filter have
been shown to help control asthma in patients with dust
mite sensitivity [116]. However, a recent study in New
York City looked at home based interventions used for
exposure reduction to indoor allergens (including but
not only dust mite) and compared it to a control group
not receiving the intervention. They found that even
though household allergens did decrease, the interven-
tion did not reduce the need for asthma medications in
already sensitized patients, while it might reduce novel
sensitizations. [113].
Despite multiple intervention trials have been con-
ducted there is still some controversy regarding the
effects of home-based exposure reduction of allergens
on asthma improvement. However, there is less compre-
hensive data on interventions outside of homes as an
important mode of exposure (i.e. schools, work places,
day care centers) and asthma control, likely due to chal-
lenges of implementing such interventions at those
levels. Considering that children spend a great amount
of their time in schools, makes schools an important tar-
get of intervention. Also finding a feasible intervention
at school level can help a group of children as opposed
to home-based interventions that can benefit only one
or a few children. There have been studies assessing sys-
tematic interventions offering medications for asthma
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control in schools, which proved to be effective [117].
However, there is a need for studies of feasible interven-
tions aimed at reducing environmental exposures such
as dust mite in schools in the future.
Group 1 allergens (e.g., Der p1, Der f1, Eur m1) of the
different HDM species form a distinct subfamily of C1
cysteine peptidases that are important in the induction
of allergic sensitization and asthma [118]. Two general
peptidase-dependent mechanisms have been identified.
One is the proteolytic attack that cleaves the epithelial
tight junctions causing an epithelial barrier damage that
facilitates allergen interaction with immune system
[119, 120]. The second is the ability of proteases to
activate signal transduction pathways of innate immunity
that induce recruitment of effector cells and promote a
Th2 biased immune response [120]. Based on the role that
the peptidase activity of group 1 HDM allergens plays in
asthma, a British group has identified a new possible
therapeutic approach using specific inhibitors of the HDM
peptidases. These new drugs, known as “allergen delivery
inhibitors” (ADIs), might provide an effective inhaled
treatment for patients suffering from allergic asthma [121].
Rhinitis/Rhinosinusitis
HDM allergens are highly prevalent, but only a minority
of people exposed to them develops clinical symptoms.
The prevalence of sensitization to mites is very high
(50–90%) in the respiratory allergic population. HDM
induced allergic rhinitis typically evolves perennial with
seasonal exacerbations in the spring and fall, which cor-
responds to an increase of proliferation of mites. The
persistent nature is more pronounced in temperate
regions while the bi-annual rhythmicity (spring and
late summer/spring) or intermittent character is more
marked in the Mediterranean regions [122]. After a
long period of evolution, these features fade and may
even disappear, the allergic condition then moving on
its own account.
It is generally believed that rhinitis due to HDM al-
lergy is more characterized by nasal obstruction than
pollen allergy. However, several studies report all nasal
symptom categories [123–125].
The diagnosis is not easy, especially in polysensitized
subjects (50–80% of HDM allergic patients). A struc-
tured history alone easily misclassifies the allergic status
in many allergic patients resulting in false positive rates
for HDM allergy of 75% [126], whereas a doctor diagno-
sis of allergic rhinitis based on the combination of an
accurate history, medical examinations and positive skin
tests can be confirmed by a positive nasal challenge to
HDM in almost all cases [127]. In the absence of pos-
sible nasal provocation test, the diagnosis is likely if all
of the following signs are present; the diagnosis is
possible if any of these signs is absent:
*symptoms are perennial with seasonal exacerbations
(Spring, Fall);
*symptoms improve in altitude (>1500 m);
*it is aggravated by contact with household dust and
domestic/indoors activities;
*skin prick test to house dust mites extract is positive.
Asthma and rhinosinusitis are common comorbid dis-
eases, without causal relationship with mite hypersensi-
tivity for the latter. In two recent SLIT trials [128, 129],
29–46% of the HDM allergic rhinitis patients included
also had asthma. Allergic rhinoonjunctivitis is less
frequent. In an analysis of children included in a
retrospective HDM SLIT study, the frequency of nasal
symptoms ranged from 89.4% for rhinorrhea to 61.7%
for nasal pruritus, whereas the frequencies of ocular
pruritus and teary eyes amounted to only 25.7 and
17.9%, respectively [125]. However, allergic rhinocon-
junctivitis should not be overlooked. Indeed, in a large
survey ocular symptoms among allergic rhinitis patients
were triggered by house dust and HDM in 34.8% [130].
The study reported a substantial impact of eye symptoms
on daily life. In another large observational, prospective
and cross-sectional study conducted in France from 2013
to 2014, 56.5% of HDM allergic patients also suffered from
conjunctivitis [131]. The strong correlation between
allergic asthma and allergic rhinitis as comorbidities
is often interpreted as evidence of an underlying com-
mon sensitization mechanism.
Atopic dermatitis
Atopic dermatitis (AD) or atopic eczema, is a prevalent
allergic disease leading to significant psycho-social
impairment and clinically relevant morbidity. It affects
both children and adults in a relapsing course [132]. AD
is characterized by a high degree of clinical heterogen-
eity. Epidemiological studies have shown that IgE
sensitization is not causative, but accompanies early skin
signs of eczema.[133, 134]
The role of sensitization to inhalant allergens in atopic
dermatitis is uncertain. Total serum IgE levels are ele-
vated but seem to be more elevated in AD patients with
filaggrin mutations [135].
Is there a role for house dust mites (HDM) in atopic
dermatitis?
1 The rate of IgE–mediated sensitization to foods and
inhalant allergens is frequent. Most AD patients
have elevated levels of serum IgE antibodies specific
to HDM allergens; furthermore biopsy specimens of
AD lesional skin have been shown to be infiltrated
with T lymphocytes that recognize Der p [136].
2 Group 1 mite allergens may facilitate its entry into
the skin by enzymatically breaking down the
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epidermal barrier [137]. This accelerates inflammation,
but does not necessarily result in specific sensitization
[37]. Mite allergens can activate keratinocytes and
induce them to produce and secrete pro-inflammatory
cytokines [137–139]. Allergens may sensitize infants
with AD via the skin. The proliferation of lymphocytes
stimulated with HDM allergens shows significantly
higher responses in AD infants than in controls.
Serum levels of HDM-specific IgE are significantly
correlated with lymphocyte stimulation index. These
results support the hypothesis that both food and
indoor allergens concurrently sensitize infants via
the skin [139].
3 Respiratory allergic diseases due to inhalant allergens
are frequent among AD patients.
4 Mites have been found in skin scrapings from
patients with AD. Patients with AD showed a higher
prevalence of mites on their skin than did healthy
individuals, which could be involved in allergic
sensitization and disease exacerbation. Though the
number of mites on clothes and bedding could be
similar in AD patients and controls [140].
5 HDM avoidance measures may reduce the eczema
[141]. Avoidance controlled trials have demonstrated
that HDM are involved in the pathogenesis of AD in
children [142, 143].
6 Epicutaneous application of HDM (Allergen Patch
Test, APT) induces AD in nonlesional skin of 50% of
AD patients [144, 145]. Thymic stromal lymphopoietin
(TSLP), a cytokine produced by epithelial
keratinocytes, plays an important role in the
pathogenesis of AD. Landheer et al. investigated
TSLP expression in nonlesional skin of AD
patients following APT with HDM extract. The
induction of TSLP protein expression occurred
only in patients with a positive APT result,
suggesting a role for TSLP in HDM induction of
AD-related eczema [146].
Is specific allergen immunotherapy an effective treat-
ment for people with atopic eczema?
Allergen-specific immunotherapy (AIT) has been used
to treat mild/moderate AD aiming to restore the imbal-
ance of the immune response [147–149]. A systematic
review of randomized controlled trials (RCTs) of specific
AIT that used standardized allergen extracts in patients
with AD has found limited evidence that specific im-
munotherapy might be an effective treatment. Subcuta-
neous and sublingual trials (10/12 trials with HDM)
were considered of low quality for the review. Treatment
was not associated with increased risk of local or sys-
temic reactions. Future studies should use high quality
allergen formulations and should include participant-
reported outcome measures [150]. In conclusion, there
is evidence that HDM are involved in the pathogenesis
of AD but the definite association between HDM allergy
and AD still remains to be firmly established.
Anaphylaxis
Anaphylaxis is an acute emergency that is potentially
fatal and commonly related to an allergic and immuno-
logic trigger requiring immediate effective life-saving
treatment [151]. Heavy mite exposure in the environ-
ment can induce allergic systemic reactions. More re-
cently, the induction of anaphylaxis through ingestion of
mite-contaminated foods has been described [152].
Pancake anaphylaxis, also called oral mite anaphylaxis
(OMA), is a relatively new syndrome characterized by
severe allergic symptoms occurring immediately after
eating foods, especially containing flours, contaminated
with mites. These cooked foods contain thermoresistant
mite allergens and contaminated wheat flour used to
make pancakes is its most common presentation [152].
A variant clinical picture is provoked by physical exercise
and is called dust mite ingestion-associated exercise-
induced anaphylaxis [153]. OMA is more prevalent in
tropical and subtropical areas of the globe where mites
grow easily in their warm and humid environments [154].
There are reports in the literature of two fatalities associ-
ated with the ingestion of foods contaminated with mites
[155, 156]. Mites responsible for OMA include domestic
and storage species and can be present in any type of
flours. There is an intriguing association of OMA and
hypersensitivity to aspirin and nonsteroidal anti-in-
flammatory drugs (NSAIDS) for which there is no good
explanation yet and it is more prevalent in patients with
house dust mite allergic rhinitis and/or asthma [157]. The
higher the contaminated mite ingestion the greater the
risk for anaphylaxis. OMA confirmation requires the
microscopic documentation and identification of mites in
the suspected flour. Alternatively the immunoassay for
demonstration of the presence of mite allergens in the
suspected flour can be used. It is imperative to try to pre-
vent the worldwide OMA delineating predisposing genetic
factors and determining if mite immunotherapy might be
efficacious modifying the clinical course of this important
variety of food anaphylaxis [152, 158].
Co-sensitization to cockroaches, some crustaceans
(shrimp, crab, lobster), shellfish (clams, mussels), and
mollusks (snails) is often described and likely due to the
presence of allergens in the tropomyosins family, present
in some crustaceans (major allergen of shrimp: Pen 1),
insects (some flies, mosquitoes, cockroaches), gastropods
and mites (Der f 10) [122].
Occupational diseases induced by mites
Exposure to storage mites has been recognized as an im-
portant cause of occupational asthma [159] and rhinitis
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[160]. An evidence-based review on causative agents of
occupational asthma identified storage mites as one of
the etiological agents with moderate evidence level in
farming and bakery [159].
The main species that have been implicated in work-
related rhinitis and asthma are Lepidoglyphus destructor,
Acarus siro/farris, Tyrophagus putrescentiae, Glycyphagus
domesticus and Blomia tjibodas [161]. Allergy to storage
mites is relatively common in subjects who work in envi-
ronments where hay and grain are handled, stored, or
processed, such as agricultural workers, farmers, millers
and bakers [162]. In addition, other professions, particu-
larly in the food industry, like poultry and ham workers,
can also develop sensitization and respiratory symptoms
due to storage mites [163]. IgE-mediated allergy to storage
mites has been demonstrated by skin prick testing and
measurements of allergen-specific IgE, and confirmed by
specific inhalation challenges [164, 165]. The occurrence
of nasal symptoms has been found to precede the devel-
opment of lower airway symptoms [160].
Although work-related allergic reactions to mites have
been mainly attributed to mites (storage), there is in-
creasing evidence showing that house dust mites (Der-
matophagoides spp.) are potential work-related risk
factors [166]. Several studies have reported high levels of
domestic mite allergens in occupational settings, particu-
larly in schools and day care centers, but clinically relevant
exposures can also been found in various workplaces,
including poultry farms, hotels, cinemas, libraries,
public transportation, fishing-boats, submarines, and
churches [166].
Sander and coworkers have assessed domestic mite aller-
gens in floor and airborne samples from workplaces and
living areas using a sensitive immunoassay to measure per-
sonal airborne mite allergen exposure [167]. These authors
found that inhalable dust mite allergen concentrations in
most of the workplaces investigated were higher than those
in living areas, and significant differences were found for
textile recycling, bed feather filling, feed production, grain
storage and cattle stables [167]. These studies [166, 167]
show that exposure to house dust mite allergens can be
higher in occupational than in domestic settings, and
therefore subjects sensitized to house dust mites can ex-
perience worsening or aggravation of respiratory symptoms
in the workplace, leading to work-exacerbated asthma.
Regarding the importance of domestic animals in mite
sensitization, pets (dogs, cats) are important carriers and
reservoirs of HDM and interestingly, D. farinae is much
more important as an allergen for allergic canines them-
selves than D. pteronyssinus, whereas the major aller-
gens have been defined as Der f 15 and Der f 18 on the
molecular basis [168].
Spider mites (family Tetranychidae, suborder Prostig-
mata, order Acari) are outdoor phytophagous mites that
damage fruit leaves. Several case reports and cross-
sectional surveys have demonstrated that spider mites
are important causative allergens of rhinitis and asthma
in fruit farmers and greenhouse workers [169]. The two-
spotted spider red mite (Tetranychus urticae) is the
most common in pear farms, greenhouses and herb-
aceous plants, whereas the European red mite (Panony-
chus ulmi) is the most frequent pest in apple farms, and
the citrus red mite (Panonychus citri) is usually found in
citrus farms and orange groves.
Predatory beneficial mites, such as Amblyseius cucumeris
and Amblyseius californicus, are increasingly being used as
biological control measures in horticulture, and these
mites have been shown to give rise to IgE-mediated
sensitization and skin rashes, conjunctivitis, rhinitis [170]
and occupational asthma [171] among exposed green-
house employees.
Diagnosis and usefulness of component resolved
diagnosis (CRD). Molecular diagnosis
Diagnosis of house dust mite (HDM) allergy is routinely
performed with crude mite extracts which contain a
mixture of allergenic and non-allergenic components in
variable amounts and are only standardized for group 1
and/or group 2 allergens. Other important allergens,
e.g., Der p 23 [172, 173] are only present in small
amounts in many commercial HDM extracts and often not
detectable [174]. Therefore, patients without sensitization
to group 1 or group 2 allergens are often not diagnosed
with mite extracts and diagnosis with mite extracts cannot
determine the allergens which are responsible for the al-
lergy [174]. A molecular diagnosis with all important
HDM allergens allows the diagnosis of all HDM allergic
patients and the determination of the exact sensitization
profile of a patient, thus determining the disease-causing
allergens. Molecular diagnosis of HDM allergy can be per-
formed by ImmunoCAP (Thermofisher, Uppsala, Sweden)
for nDer p 1, rDer p 2 and the mite tropomyosin, rDer p
10, or by allergen microarray chip (ImmunoCAP ISAC
Test, Thermofisher), which contains the same HDM
allergens. However, not all HDM allergic patients can
be diagnosed with these allergens and it has been
shown that 5% of HDM allergic patients are mono-
sensitized to Der p 23 [175].
Recently, within the MeDALL (Mechanisms of the De-
velopment of ALLergy) project, a customized allergen-
chip was developed which contained the most important
HDM allergens (Der p 1, 2, 4, 5, 7, 10, 11, 14, 15, 18, 21
and 23) [176, 177] and which was comparable to skin
prick testing and ImmunoCAP for diagnosis of allergic
rhinitis and asthma [178]. A component-specific diagno-
sis allows the determination whether a patient is genu-
inely sensitized to HDMs (e.g., IgE-reactivity to Der p 1
or Der p 2), or if the reaction to HDMs is caused by
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cross-reactivity (e.g., exclusive sensitization to Der p 10
in shrimp allergic patients) [179]. Additionally, using
molecular diagnosis it was possible for the first time to
answer the question whether IgE reactivity profiles
change substantially or remain constant over time,
showing that de novo sensitizations to new allergens are
rare events in allergic adults [180]. A long lasting goal of
allergy research was to find markers which may predict
the development of allergy in children and the develop-
ment of severe forms of disease manifestations (e.g.,
asthma, atopic dermatitis). Using component-specific
diagnosis, it was shown that allergic rhinitis to birch
pollen in adolescence can be predicted by IgE reactivity
to pathogenesis-related class 10 proteins in early child-
hood [181] and that sensitization to Fel d 1 and Can f 1
in childhood were associated with symptoms to cat and
dog in adolescence [182]. Likewise, high Ara h 2 IgE
titers were shown to be associated with peanut-induced
anaphylaxis [183]. In the case of mite allergy, CRD with
the MeDALL chip indicated that IgE responses to mites
were initiated by Der p 1, Der p 2 or Der p 23 and in-
creased in prevalence along the first decade of life [184].
Additionally, early IgE sensitization to Der p 1 and to
Der p 23, but not to Der p 2, was significantly associated
with asthma at school age and children with broad IgE
sensitizations to mite allergens had a significantly higher
risk to develop asthma [184]. In this context, it was also
shown that mite allergic children with asthma reacted
with more HDM allergens than children without asthma
and had also higher IgE-levels to the individual allergens
than the children without asthma. In contrast, fewer
asthmatic children showed IgG reactivity to HDM aller-
gens than non-asthmatic children. In the case of
atopic dermatitis, CRD showed that allergens which
were only found in mite bodies (i.e., Der p 10, 11, 14
and Der p 18) were more often recognized by HDM
allergic patients with atopic dermatitis than by patients
with respiratory symptoms, whereas no difference in
the frequency of IgE reactivity was found to allergens
derived from faeces (i.e., Der p 1, 2, 5, 7, 21 and Der p
23) between patients with atopic dermatitis and patients
with respiratory allergy [185]. Therefore, it is possible
that atopic dermatitis patients become sensitized to mite
body-associated allergens by skin contact. In a recent
study, it was also shown that allergen contact by the
oral route induced preferentially IgG responses whereas
respiratory allergen contact was important for IgE
sensitization [186].
Specific immunotherapy with mite allergens
Allergen Immunotherapy (AIT) is widely used in clinical
practice for patients with house dust mite (HDM) al-
lergy. AIT may be delivered via subcutaneous (SCIT)
and sublingual routes (SLIT) [187]. AIT is a therapeutic
intervention which is adapted to the specific IgE
spectrum of an individual and modifies the natural
course of the disease as it has a persistent efficacy after
completion of treatment. In this perspective, AIT has to
be presently considered a prototype of Precision Medi-
cine [188].
Despite the global use of HDM-AIT, documentation
on its efficacy has been controversial [189]. This is
mainly due to the clinical and methodological hetero-
geneity amongst studies [122]. Generalised conclusions
(“class effects”) on the efficacy and disease-modifying ef-
fects to all AIT products are unjustified. In contrast,
each product needs to be evaluated individually, based
on available study results, to justify efficacy and specific
claims on sustained and disease modifying effects per
allergen and targeted patient group (children vs. adults,
allergic rhinitis vs. asthma) [190].
Allergic Rhinitis
AIT has been included as a therapeutic intervention in
the management of AR in the ARIA guidelines. Evidence
on AIT efficacy has been thoroughly evaluated. In the
sub-analysis of the SLIT Cochrane systematic review and
meta-analysis, Radulovic et al. [191] found a significant
reduction in symptom scores (SMD −0.97; CI −1.8 to
−0.3; p = 0.02; n = 464 patients) and in medication scores
(SMD −0.52; CI −1.09 to −0.03, p = 0.07; n = 189
patients) compared with placebo (Fig. 4).
Recently, a pan-European double-blind placebo-
controlled randomized controlled (DB PC RCT) trial
that included 992 adults with moderate-to-severe
HDM-induced AR despite treatment with pharmaco-
therapy was published [192]. Analysis of the primary
end point demonstrated absolute reductions in total
combined rhinitis score of 1.18 (p = 0.002) and 1.22
(p = 0.001) compared with placebo for 6 SQHDM and
12 SQ-HDM, respectively. The statistically significant
treatment effect was evident from 14 weeks of treat-
ment onward. The treatment was well tolerated.
The safety of the new SLIT-HDM tablet has been eval-
uated in a multicentre, DB PC RCT in North American
children 12 to 17 years old with HDM AR with and
without conjunctivitis and with or without asthma [193].
The 6 and 12 SQ-HDM doses of the HDM SLIT-tablet
were well tolerated, and local AEs were of short dur-
ation. No anaphylactic reactions, systemic allergic reac-
tions, AEs requiring epinephrine, serious AEs, or local
swellings in the mouth or throat assessed as severe were
reported.
AIT in allergic asthma to HDM
Although AIT is widely used in children and adults with
HDM-Asthma, the level of evidence for its efficacy and
safety is still a matter of debate. Many different individual
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publications and systematic reviews have shown superior-
ity of SCIT [194] and SLIT [195] over placebo. However,
the majority of these studies were heterogeneous for aller-
gen dose, duration, and patient selection.
For SCIT, in a sub-analysis of 12 studies [194] a re-
duction in asthma symptom scores (SMD −0.48; CI
95% –0.96 to −0.00; n = 408) and asthma medication
scores (SMD −0.61; CI 95% –1.04 to −0.18; n = 424)
was found. For SLIT, nine DB PC RCT studies evalu-
ated the effect of HDM-SLIT over placebo [195]. The
authors found a significant reduction in asthma symp-
toms (SMD −0.95; CI 95% –1.74 to −0.15, p = 0.02; n
= 243 patients) and a reduction in rescue medication
use (SMD −1.48; CI 95% –2.70 to −0.26; p = 0.02; n =
202 patients) (Fig. 5).
The efficacy and safety of the new HDM-SLIT tablet
was first evaluated as steroid sparing treatment while
keeping asthma control [196]. More recently, in an
European double-blind placebo-controlled randomized
trial 834 adult patients with HDM-AA and HDM-AR,
which were not well controlled by inhaled corticoste-
roids (ICS) were included [197]. Patients were treated
daily for 12 months with either a 12 SQ-HDM or a 6
SQ-HDM dose, or with placebo in addition to ICS and
short-acting beta-agonists (SABA). The trial showed that
12 SQ-HDM (the dose approved in the EU) significantly
reduced the risk of a moderate or severe asthma exacer-
bation relative to placebo with a hazard ratio (HR) of
0.66, corresponding to a 34% risk reduction. This
includes a 36% reduction in risk of nocturnal awakening
or increase in daily symptoms (HR: 0.64) and a 48%
reduction in the risk of increased use of SABA treat-
ments (HR: 0.52) [197].
AIT in atopic dermatitis to HDM
At present, few studies have evaluated the efficacy of
AIT (both SCIT and SLIT) in atopic dermatitis (AD).
Some studies have demonstrated good efficacy effect,
although there are conflicting data on which patient
population benefits, for example, moderate versus severe
AD. The clinical and methodological heterogeneity in
these studies is a limitation to make comparisons, thus,
nearly impossible to base conclusions about the treat-
ment efficacy. More research is needed with randomised
trials of well-defined patient populations with AD using
uniform, standardized outcomes to establish compara-
tive effectiveness of AIT in AD [198].
Prevention of Dust Mite and Dust Mite Allergen Exposure
Justification for Dust Mite Exposure Control
The decision to initiate environmental controls to re-
duce dust mite exposure can be complex. Total preven-
tion of exposure to mite allergenic material to prevent
IgE sensitization to mite allergens in genetically suscep-
tible individuals requires strict, continuous avoidance of
mite exposure, which is practically all but impossible
[199]. Furthermore, to curtail development of all cross-
reacting specific IgE, avoidance of all arthropods would
Fig. 4 Allergen Immunotherapy for HDM-induced Rhinitis. Adapted from: Moisés A. Calderón, Jörg Kleine-Tebbe, Allan Linneberg, Frédéric De
Blay, Dolores Hernandez Fernandez de Rojas, Johann Christian Virchow, Pascal Demoly. House Dust Mite Respiratory Allergy: An Overview of
Current Therapeutic Strategies The Journal of Allergy and Clinical Immunology: In Practice 2015; 3(6): 843–855. http://dx.doi.org/10.1016/
j.jaip.2015.06.019. Adapted under the Open Access Creative Commons License. The authors have used Fig. 3a, Immunotherapy. Calderon MA et al. J
Allergy Clin Immunol In Practice 2015; 3: 843-55. 1Calderon MA et al. Cochrane Database of Systematic Reviews 2013. No.: CD007163[In prees]. 2Radulovic
S et al. Cochrane Database Syst Rev. 2010 Dec. 8:(12):CD002893
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probably be required [200]. The majority of the world’s
population lives on seacoasts [201] or along rivers [202]
and these areas typically have adequate humidity to sup-
port growth of dust mites and storage mites during all
parts of the year.
Much research has been conducted to determine if it
is possible to reduce development of mite-specific IgE-
mediated sensitization (primary prevention). Several
studies comparing dust mite sensitization rates in c-
hildren from areas endemically low and areas endemic-
ally high in dust mite allergen indicated that the
prevalence and degree of sensitization to dust mite was
strongly associated with the amount of exposure to mite
allergens [203, 204]. A prospective study of mite allergen
avoidance in Manchester, UK, [205, 206] using a com-
bination of interventions, decreased Der p 1 from mat-
tresses by 97% to the nanogram range during pregnancy
and 12 months after birth in the active group [205].
However, with all possible dust mite exposures at homes
of friends and family, on public transportation and in
public places and at schools and day care centers, pri-
mary prevention of dust mite sensitization by mite aller-
gen avoidance may not be possible [207–209].
Secondary prevention, or the attempt to reduce the
risk of asthma in dust mite sensitized children has also
received much attention. The link between asthma and
dust mite exposure is one of the most extensively studied
relationships between environmental exposure and disease
development [210–213]. In all climates conducive to the
growth of dust mites, mite exposure may be one of the
factors contributing to the development of asthma
[112, 214]. Secondary prevention has also been the
goal for many children with allergic rhinitis who are
at risk of the subsequent development of asthma.
However, to date there is no evidence-based informa-
tion as to whether mite avoidance may be effective as
a secondary preventive measure to prevent/delay
asthma development among mite-sensitized individ-
uals, or those with allergic rhinitis.
The relation of dust mite allergen exposure and the
worsening of allergic respiratory symptoms is well docu-
mented [215]. In one study of 311 subjects both sensi-
tized and exposed to high levels of indoor allergen
including dust mite allergen there was significantly lower
FEV1% predicted values (mean, 83.7% vs 89.3%; mean
difference, 5.6%; 95% CI, 0.6%-10.6%; P = .03), higher
eNO values (geometric mean [GM], 12.8 vs 8.7 ppb; GM
ratio, 0.7; 95% CI, 0.5-0.8; P = .001), and more severe air-
ways reactivity (PD20 GM, 0.25 vs 0.73 mg; GM ratio,
2.9; 95% CI, 1.6-5.0; P < .001) as compared with subjects
not sensitized and exposed [216]. Adults in a 4-year
study who were both sensitized and exposed to high
levels of dust mite allergens had increased bronchial
hyper-responsiveness [217]. Many additional links be-
tween dust mite exposure and allergic disease are docu-
mented in the recent environmental practice parameter
Fig. 5 Allergen Immunotherapy for HDM-induced Asthma. Adapted from: Moisés A. Calderón, Jörg Kleine-Tebbe, Allan Linneberg, Frédéric De
Blay, Dolores Hernandez Fernandez de Rojas, Johann Christian Virchow, Pascal Demoly. House Dust Mite Respiratory Allergy: An Overview of
Current Therapeutic Strategies. The Journal of Allergy and Clinical Immunology: In Practice 2015; 3(6): 843–855. http://dx.doi.org/10.1016/
j.jaip.2015.06.019. Adapted under the Open Access Creative Commons License. The `s have used Fig. 3b, Immunotherapy. Calderon MA et al. J
Allergy Clin Immunol In Practice 2015; 3: 843-55. 1Abramson MJ et al. Cochrane Database Syts Rev. 2010 Aug 4: (8): CD001186. 2Calamita Z et al.
Allergy 2008 ; 62: 1162-72
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on dust mites [198]. A reduction in the symptoms expe-
rienced by those with atopic dermatitis has also been
linked to house dust-mite allergen avoidance [218].
Facilitative factors and Allergen Reservoirs
Controlling factors that facilitate the growth and
reproduction of dust mites has been an often sought
goal in exposure control. The dependence of dust mites
on the water content of the air has been extensively doc-
umented [219, 220]. Arid climates have an intrinsically
low abundance of dust mites, and the most effective
method of controlling dust mite exposure is to live in a
very dry climate such as the high desert of New Mexico
in the US or the Altiplano or Bolivian Plateau, in west-
central South America [202]. Since this is not a practical
solution, mimicking these conditions in the home envir-
onment as much as possible provides an opportunity to
control mite population growth.
Humidity control should be the mainstay of any mite
control efforts. The most important factor facilitating
dust mite growth, reproduction and allergen production
is the availability of water in the surrounding environ-
ment [220]. Mites absorb moisture directly from their
surroundings under conditions of high moisture and lose
water when moisture is low. The mite moisture equilib-
rium therefore is not directly relative humidity dependent.
It is instead dependent of the moisture situation of the
local microenvironment and the moisture retention ability
of the mite’s immediate surroundings such as carpet dust
reservoirs or bedding. A simple measurement of relative
humidity may not assure an environment free of dust mite
activity. Microenvironments that exist in bedding, in car-
pet next to concrete or in pet lounging areas may provide
adequate moisture for mite survival in climates not ex-
pected to have a mite presence. A mite surrounded by a
hygroscopic microenvironment as moist bedding can sur-
vive much dryer conditions than would be expected. Of
note, exposure to a moisture rich environment for only a
short period can provide enough moisture for growth and
metabolism [221].
Although directly linked to water content of the air in
the calculation of relative humidity, temperature is also
a factor in dust mite survival. Conditions at the extreme
ends of the temperature spectrum, either to cold or to hot
can impact mite survival although elevated temperature
conditions tend to be more lethal than freezing. Mites and
their eggs survive poorly when exposed to hot water and
clothes dryers but survive during short periods of freezing
conditions. The exposure to direct sunlight is an often
forgotten factor in the destruction of dust mites [222].
It is not enough to address mite factors facilitating
mite population growth. Reservoirs of mite allergen
must also be eliminated. House dust mites can be found
in any area of the home, however they are most often
associated with certain indoor environments including
the bedroom carpet, mattresses and bedding, frequently
occupied upholstered furniture and in pet lounging areas
[223, 224]. Recent investigations have questioned the
traditional concepts of the location of dust mite reser-
voirs indicating that significant exposure can occur in
public transportation conveyances and associated with
work environments as well as clothing [207].
Climate Factors
Although residents of cold and arid climates are less
likely to be exposed to house dust mites, the large majority
of the world population is exposed to house dust mites.
Nearly half of the people in the world live within 200 km
of the coast where humidity levels are typically higher.
The rate of population growth in coastal areas is accelerat-
ing. In China alone over 400 million live in coastal cities.
Dust mite exposures and the allergic problems related to
those exposures are likely to increase [201].
Although many climates are naturally conducive to
mite growth and allergen production, the artificial con-
trol of indoor climates is increasing. Even though it is
energy intensive, the use of forced air heating and air
conditioning is growing around the world and especially
in more affluent economies. Dust mite allergen exposure
control is therefore a viable option for large numbers of
persons. In many areas seasonal heating requirements
result in very dry indoor environments and subsequently
dust mite exposure is a seasonal phenomenon. Low hu-
midity conditions can also be obtained through use of
air conditioning and dehumidification. Yet, in many
areas of the world ambient humidity levels are high
enough that producing low humidity levels sufficient to
preclude dust mite growth is not practically achievable.
The recent Cochrane study on dehumidification alone
indicates that evidence of clinical benefits of dehumidifi-
cation using mechanical ventilation with dehumidifiers
is scanty [225]. Indeed, the meta-analysis of multiple
dust mite control studies would lead the reader to be-
lieve that there is nothing that can be physically done to
control dust mites and improve health. Yet, this conclu-
sion is disputed by many experts in the field of allergy
[226]. Furthermore, the nature of single source exposure
control studies may preclude successful clinical improve-
ment because allergen sensitization is typically to mul-
tiple agents.
A significant amount of work has been done on re-
moval of mites and mite allergens through cleaning. It
goes without saying that efforts to control mite infesta-
tions of the skin and remove mite infestations from
clothing are essential in the maintenance of overall
health [227]. Humans have been living with dust mites
for generations and they might even be described as
among our “old friends” [228]. But no physician would
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advocate for wearing mite infested clothing or sleeping
in mite infested bedding. Mite sensitization is likely to
occur in genetically susceptible individuals, therefore
efforts to reduce instances of elevated mite exposure and
thus reduce allergic symptoms are only prudent [229].
Since mite allergens are located in known areas of a
typical house [229, 230] removing mite allergen reservoirs
is a very effective way to reduce mite allergen exposure.
Efforts to remove carpets, drapes, upholstered furniture
and any other fabric covered objects from the living envir-
onment can effectively reduce mite allergen exposure. The
extent to which these items are removed will ultimately be
a matter of personal preference. Since mite allergens are
known to be heavy and not aerodynamically suited for air-
borne disbursal [34] and high humidity microenviron-
ments are known to exist in bedding it is logical to focus
dust mite reduction efforts on bedding. Efforts to enclose
mattresses, box springs and pillows in mite-impermeable
covers are known to be very effective [231]. However, it is
important to mention that the efficacy of allergen avoid-
ance in patients with already established rhinitis or asthma
is a matter of debate [232–235].
Washing bedding in hot water and even with bleach
and drying bedding in very hot conditions or even in dir-
ect sunlight are known to reduce both the presence of
mite allergen and the mites themselves [236, 237].
Washing bedding and clothing removes mite allergens
and kills mites. Most of the killing is through drowning,
although washing in hotter water kills more mites. The
temperature used to wash bedding has become an issue.
Elevated temperatures are more energy intensive and
hotter water is a scalding hazard. Experts agree that
washing is better than not washing and washing with
water that is 48° Celsius provides optimum mite killing
and home safety [199].
Heat treatment can be effective in killing mites and
their eggs. Treatment of cloth at 95° Celsius killed all
mites present [238]. However, treatment at 40 °C under
dry and wet conditions allowed approximately 80% of all
mite eggs to survive. Under dry heat at 50 °C, the ther-
mal death point of dust mite eggs occurred at 5 h and at
60 °C death occurred almost instantaneously [239]. Pre-
sumably the eggs survive heat better than the mites
themselves. Homes treated with heat-steam over a
period of months showed a sustained reduction of Der p
1 and Der p 2 compared to sham treated homes [240]
However, mite allergens have been demonstrated to be
stable even at elevated temperatures [241].
Although the practice has fallen into senescence in the
modern world of appliances, there was a time when fre-
quently placing bedding in direct sunlight for several
hours was practiced in many cultures. It has been dem-
onstrated that ultraviolet irradiation is lethal to many
organisms including dust mites [242, 243].
Many harsh chemicals are known to kill dust mites or
denature mite allergens in industrial and household set-
tings. Agents like tannic acid, Benzyl benzoate, Diso-
dium octaborate tetrahydrate, tri-n-butyl tin maleate,
pirimiphos methyl and even “essential oils” like methyl
eugenol have been described in the literature to effect-
ively kill mites [244–248]. However, they are all danger-
ous at some concentration and cannot be recommended
for use by patients or homeowners [199].
It has been suggested that freezing can be effective in
killing dust mites and the recommendation to place
small cloth items like stuffed animals in the freezer com-
partment of house hold refrigerators has been frequently
given out by allergists. However, there is little evidence
that this is effective. There may be some mite death due
to desiccation in the dry environment of a household
freezer. But, dust mite eggs have been shown to resist
freezing at temperatures above −70° Celsius [222]. And,
freezing is not effective in removing dust mite allergen
from reservoirs because dust mite allergen is stable at
low temperatures for extended periods of time [239].
Air conditioning would have a twofold impact on dust
mite populations. The cool temperatures will slow mite
metabolism and reproduction and reduce moisture need
for mite survival. Microenvironments or increased humid-
ity can be reduced using a dehumidifier and/or air condi-
tioning. The absence of air conditioning has been shown
to be a factor contributing to increased mite allergen levels
in US homes [249]. Air conditioners must be operated for
a long time to remove sufficient moisture from the air to
effectively decrease room humidity. Mechanical ventilation
heat pump recovery units in the UK failed to achieve the
desired mite reduction results [250].
Evidence on clinical benefits of dehumidification using
mechanical ventilation with dehumidifiers remains
scanty [225]. Although dehumidification and air condi-
tioning doubtlessly reduce overall dust mite exposure
[251], the difficulty in using dehumidification alone in
damp environments to decrease dust mite antigen expos-
ure has been described in a recent Cochrane review [225].
Summary of current recommendations
Most publications on allergy and dust mite control would
agree that a comprehensive program of personal hygiene,
bed hygiene, properly fitted allergen-impermeable covers,
cleaning, dehumidification or air conditioning and appro-
priate food storage in very damp climates can reduce ex-
posure to house dust mite allergens. It is a stretch further
to conclude that the above steps can improve symptoms
in those already allergic to dust mites. However, depend-
ing on the sensitivity and life style of the allergic person,
prudent efforts over an extended period of time are likely
to result in gradual improvement in health. The fact that
current studies do not provide sufficient evidence for
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critical reviews to conclude there is unequivocal benefit is
no reason to abandon logical and prudent efforts to
reduce mite exposure.
Unmet Needs in Mite Allergy Research
The authors view the following as currently unmet needs
in mite allergy research:
 Since mites constitute the most important allergen
source worldwide the information contained in this
document needs to be disseminated to all ranks of
the medical establishment for educational purposes
and to stimulate research
 Increased knowledge on the cellular basis of the
immune responses to mites
 A better understanding of the link between mite
sensitization and allergic diseases
 Better insights into the genetic influences controlling
IgE responses to mite allergens. Effects of epigenetic
factors
 Improved mite allergen standardization
 Development of purified mite allergens with defined
clinically relevant epitopes for molecular diagnosis
and evaluation of the response to immunotherapy
 Development of objective methods to assess allergen
exposure and environmental control outcomes
 Better strategies for immunotherapy and
immunoprophylaxis of mite allergy: recombinant
allergens, hypoallergens, T cell peptides.
 Performance of controlled immunotherapy trials
with high quality allergen formulations using
standardized outcomes
 New strategies for primary and secondary prevention
of mite-induced diseases
 Primary prevention efforts might be strengthened
with a better understanding of the link between mite
sensitization and allergic disease
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